David Kroin: Stock Portfolio, Performance and Latest Trades
Deep Track Capital
13F portfolio value
$6.9B
67 holdings at Q2 2026
Get an email when David Kroin files a new 13F report
Free, no account needed. Unsubscribe with one click.
David Kroin's portfolio
As of Q2 2026, filed August 14, 2026 · prices as of October 8, 2026
| Company | Share of portfolio | Average buy price | Return | Current price | Last quarter |
|---|---|---|---|---|---|
| 7.50% | $41.93 | +295% | $165.56 | Added +1.6% | |
Immunovant Inc.IMVT | 5.30% | $24.15 | +25.3% | $30.26 | Reduced −19% |
| 3.75% | $33.65 | −23.7% | $25.67 | Added +11% | |
Vaxcyte Inc.PCVX | 3.68% | $38.00 | +71.1% | $65.02 | No change |
| 3.66% | $301.61 | −25.6% | $224.53 | New | |
Veradermics Inc.MANE | 3.62% | $82.87 | +52.8% | $126.63 | Added +300% |
| 3.40% | $52.66 | +37.2% | $72.22 | Added +1.9% | |
Nuvalent Inc.670703107 | 3.24% | $107.25 | — | — | Added +30% |
Alkermes PLCALKS | 3.09% | $31.31 | +28.1% | $40.11 | Added +11% |
| 2.85% | $7.47 | +0.5% | $7.51 | No change | |
| 2.79% | $54.67 | +0.4% | $54.89 | Added +188% | |
| 2.76% | $14.56 | +52.5% | $22.21 | Added +22% | |
| 2.70% | $19.06 | +305% | $77.28 | Reduced −5.3% | |
Alumis Inc.ALMS | 2.63% | $22.03 | −68.4% | $6.97 | Reduced −6.3% |
| 2.57% | $45.35 | −4.5% | $43.30 | Added +13% | |
| 2.54% | $4.99 | +130% | $11.47 | No change | |
| 2.53% | $37.89 | −21.5% | $29.73 | Reduced −2.6% | |
| 2.52% | $113.80 | +49.5% | $170.08 | Reduced −36% | |
| 2.29% | $28.78 | +25.3% | $36.05 | Added +54% | |
| 2.01% | $13.56 | −22.0% | $10.58 | Added +9.2% | |
| 1.95% | $27.59 | +12.0% | $30.89 | New | |
| 1.93% | $13.91 | +62.3% | $22.57 | Added +53% | |
| 1.91% | $16.97 | +101% | $34.18 | Reduced −8.3% | |
Grail Inc.GRAL | 1.85% | $71.47 | +85.5% | $132.61 | Added +6.5% |
| 1.79% | $19.09 | −9.6% | $17.26 | Added +0.9% | |
| 1.64% | $14.22 | +82.0% | $25.88 | Added +7.3% | |
| 1.61% | $29.57 | −0.9% | $29.30 | Added +129% | |
| 1.60% | $15.79 | +119% | $34.61 | No change | |
| 1.41% | $23.42 | +127% | $53.25 | Reduced −37% | |
GH Research PLCGHRS | 1.32% | $20.88 | −2.0% | $20.45 | New |
| 1.14% | $35.64 | −15.6% | $30.08 | Added +100% | |
Ataibeckley Inc.04650F101 | 1.12% | $3.83 | — | — | Added +20% |
| 0.99% | $563.19 | −5.4% | $532.78 | New | |
| 0.98% | $15.81 | −15.0% | $13.43 | New | |
| 0.97% | $16.93 | +8.3% | $18.34 | Added +158% | |
| 0.88% | $47.92 | +29.4% | $62.01 | Reduced −49% | |
| 0.86% | $2.99 | −12.9% | $2.60 | New | |
Personalis Inc.PSNL | 0.79% | $8.37 | +92.0% | $16.06 | Added +33% |
| 0.73% | $3.37 | +12.3% | $3.79 | No change | |
Cormedix Inc.CRMD | 0.73% | $10.55 | −30.6% | $7.32 | No change |
| 0.71% | $68.65 | −1.3% | $67.73 | New | |
Harrow Inc.HROW | 0.61% | $37.20 | −18.0% | $30.52 | New |
| 0.55% | $14.63 | −30.2% | $10.21 | Added +0.0% | |
| 0.52% | $6.43 | +6.1% | $6.82 | No change | |
| 0.51% | $28.19 | −12.7% | $24.60 | Added +22% | |
| 0.49% | $13.25 | +23.5% | $16.37 | Reduced −25% | |
| 0.42% | $9.28 | +0.1% | $9.29 | New | |
| 0.40% | $3.62 | −22.9% | $2.79 | Reduced −7.3% | |
| 0.38% | $6.24 | −9.3% | $5.66 | New | |
Mannkind Corp.MNKD | 0.38% | $3.25 | +5.3% | $3.42 | New |
| 0.34% | $2.10 | −30.6% | $1.46 | Reduced −0.3% | |
| 0.33% | $13.62 | +2.7% | $13.99 | New | |
Verastem Inc.VSTM | 0.32% | $8.91 | −9.0% | $8.11 | No change |
| 0.32% | $8.59 | +22.5% | $10.52 | Reduced −25% | |
| 0.31% | $12.70 | −4.7% | $12.10 | Reduced −26% | |
| 0.31% | $73.17 | −44.2% | $40.80 | New | |
| 0.28% | $13.40 | −41.6% | $7.82 | New | |
| 0.23% | $21.98 | −54.5% | $10.00 | New | |
Kardigan Inc.KARD | 0.21% | $23.85 | −40.5% | $14.20 | New |
| 0.17% | $42.45 | −4.3% | $40.63 | New | |
| 0.16% | $14.91 | −38.6% | $9.15 | No change | |
| 0.15% | $31.16 | −6.7% | $29.09 | Reduced −84% | |
Xencor Inc.XNCR | 0.14% | $12.49 | +96.2% | $24.50 | New |
| 0.06% | $1.72 | −82.7% | $0.299 | No change | |
| 0.04% | $5.52 | −39.8% | $3.32 | Reduced −35% | |
| 0.04% | $16.71 | −68.2% | $5.31 | No change |
David Kroin's options
As of Q2 2026. Value = shares the options cover.
| Company | Type | Value of shares covered | Last quarter |
|---|---|---|---|
| Call · bet on a rise | $82.4M | New | |
| Put · bet on a fall or hedge | — | Sold out |
David Kroin's buys and sells
| Company | Action | Shares change | Value now |
|---|---|---|---|
Intra-Cellular Therapies Inc.46116X101 | Sold out | −2,000,000 | — |
Insmed Inc.INSM | Added +587% | +1,495,249 | $176.1M |
| New | +801,371 | $83.7M | |
| Reduced −68% | −1,900,000 | $38.9M | |
| Added +7.2% | +327,337 | $193.3M | |
| Reduced −71% | −639,931 | $4.4M | |
Vaxcyte Inc.PCVX | Added +187% | +1,400,000 | $69.9M |
| Added +25% | +1,033,917 | $106.5M | |
Amgen Inc.AMGN | Sold out | −113,035 | — |
| Added +8.2% | +245,899 | $179.4M | |
Akero Therapeutics Inc.00973Y108 | Reduced −5.2% | −167,672 | $162.4M |
| Sold out | −1,400,000 | — | |
89bio Inc.282559103 | Added +2.0% | +183,667 | $93.3M |
| New | +2,509,301 | $25.1M | |
| Sold out | −2,000,000 | — | |
| Sold out | −741,068 | — | |
Sage Therapeutics Inc.78667J108 | Sold out | −2,038,845 | — |
| Added +28% | +388,598 | $56.5M | |
Merus NVN5749R100 | New | +275,000 | $14.5M |
Terns Pharmaceuticals Inc.880881107 | Added +34% | +1,918,442 | $28M |
| Added +21% | +679,784 | $48.5M | |
| New | +250,000 | $12.2M | |
Apellis Pharmaceuticals03753U106 | Added +40% | +2,000,000 | $121.2M |
Korro Bio Inc.KRRO | Reduced −68% | −596,648 | $3.5M |
| Reduced −5.6% | −997,335 | $38.4M | |
| Reduced −22% | −1,193,721 | $221.2M | |
Septerna Inc.SEPN | Reduced −94% | −1,791,213 | $1.3M |
| Added +35% | +350,000 | $42.3M | |
Sarepta Therapeutics Inc.PutSRPT | New | +450,000 | $7.7M |
Rapt Therapeutics Inc.75382E109 | Sold out | −6,011,380 | — |
| New | +453,686 | $7.3M | |
| Added +33% | +474,089 | $21.5M | |
Centessa Pharmaceuticals-Adr152309100 | New | +500,000 | $6.6M |
| Sold out | −315,765 | — | |
| New | +751,422 | $6M | |
| Sold out | −3,262,564 | — | |
| Added +18% | +265,734 | $70.9M | |
Abivax Sa-AdrABVX | Reduced −2.8% | −99,065 | $26.6M |
| Reduced −34% | −292,773 | $2.8M | |
| Added +10% | +564,910 | $69.1M | |
| Added +21% | +426,657 | $22.5M | |
| Reduced −79% | −359,319 | $1.1M | |
Novavax Inc.NVAX | Reduced −34% | −519,640 | $6.3M |
| Added +19% | +576,147 | $120.6M | |
| Reduced −27% | −1,451,874 | $4.6M | |
| Reduced −28% | −830,343 | $25M | |
Zura Bio Ltd.ZURA | Reduced −47% | −1,556,221 | $1.8M |
| Added +57% | +436,228 | $8.4M | |
| Reduced −66% | −343,479 | $431.4K | |
| Reduced −37% | −856,800 | $15.8M | |
Allakos Inc.01671P100 | Sold out | −7,232,701 | — |
Neurogene Inc.NGNE | Sold out | −116,660 | — |
| Reduced −5.3% | −124,554 | $41.6M | |
| Reduced −36% | −1,137,792 | $4M | |
| Reduced −0.3% | −28,641 | $24.7M | |
Invivyd Inc.IVVD | Reduced −12% | −1,136,274 | $6.1M |
Geron Corp.GERN | Added +13% | +4,823,749 | $60.6M |
David Kroin's portfolio by sector
Share of the stock portfolio at Q2 2026.
| Sector | Share |
|---|---|
| Health Care | 96% |
| Other | 4.4% |
Portfolio performance: David Kroin vs. benchmarks
Your result if you had bought each reported portfolio on the day it was made public and held it until the next report, against the S&P 500 and Nasdaq-100.
- You, copying after each 13F filing – estimated value
- S&P 500
- Nasdaq-100
| Total return | Per year | |
|---|---|---|
| You, copying after each 13F filing – estimated value | +83.0% | +13.9% |
| S&P 500 | +87.8% | +14.5% |
| Nasdaq-100 | +121.4% | +18.7% |
Prices were available for 70% of the portfolio value on average; the rest is left out of the return.
David Kroin's most traded stocks
Quarters with a buy or a sell, all reports since Q4 2021.
| Company | Quarters bought | Quarters sold |
|---|---|---|
| 5 | 11 | |
Immunovant Inc.IMVT | 9 | 7 |
Geron Corp.GERN | 7 | 8 |
| 8 | 7 | |
| 8 | 5 | |
| 9 | 4 | |
| 8 | 5 | |
| 8 | 5 | |
| 7 | 6 | |
| 8 | 4 | |
| 8 | 4 | |
| 7 | 5 | |
| 7 | 5 | |
| 7 | 4 | |
| 9 | 2 |